Oct 04, 2021
STAMFORD, Conn. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented results from
Additional Formats
Aug 23, 2021
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with reimbursement in H1 2022 Company to host conference call today
Additional Formats
Aug 09, 2021
– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.
Additional Formats
Displaying 1 - 10 of 19
Contact IR
email alerts